Reports Q4 revenue $31M, consensus $32.62M. "Once again OrthoPediatrics produced record revenue and growth in excess of 20% continuing a trend that has been ongoing since our inception, excluding the pandemic ridden 2020. More specifically, we made key strides in attracting new users and gaining share within our core businesses, both domestically and abroad, while also capitalizing on the synergies from our two Trauma & Deformity acquisitions, MD Orthopaedics and Pega Medical," commented CEO David Bailey. "Looking ahead, we remain dedicated to surrounding surgeons with the most comprehensive portfolio of pediatric orthopedic solutions and helping more kids than ever before. We are excited about our growth prospects and are confident we can improve our profitability in 2023."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on KIDS:
- OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2022 Financial Results
- OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2022 Financial Results on March 1, 2023
- OrthoPediatrics publishes ESG summary report
- OrthoPediatrics Corp. Publishes Environmental, Social, and Governance (“ESG”) Summary Report
- OrthoPediatrics price target raised to $56 from $47 at Truist
